Copernicus Capital Management, LLC Buys Bristol-Myers Squibb Company, UnitedHealth Group Inc, IQVIA Holdings Inc, Sells Merck Inc, Intuitive Surgical Inc, Illumina Inc

• New Purchases: BMY, UNH, IQV, HPR, NVRO,
• Added Positions: HRTX, ZTS, CDNA,
• Reduced Positions: ISRG, ILMN, GILD, VRTX, SYK,
• Sold Out: MRK, CVS, WCG, AGN,

For the details of Copernicus Capital Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/copernicus+capital+management%2C+llc/current-portfolio/portfolio

1. Thermo Fisher Scientific Inc (TMO) - 18,990 shares, 13.33% of the total portfolio. Shares reduced by 0.05%
2. Zoetis Inc (ZTS) - 50,413 shares, 13.01% of the total portfolio. Shares added by 10.95%
3. Bristol-Myers Squibb Company (BMY) - 85,000 shares, 10.40% of the total portfolio. New Position
4. Heron Therapeutics Inc (HRTX) - 135,946 shares, 8.52% of the total portfolio. Shares added by 46.18%
5. Vertex Pharmaceuticals Inc (VRTX) - 17,863 shares, 8.43% of the total portfolio. Shares reduced by 45.68%

Copernicus Capital Management, LLC initiated holding in Bristol-Myers Squibb Company. The purchase prices were between $45.12 and $53.8, with an estimated average price of $49.88. The stock is now traded at around $46.63. The impact to a portfolio due to this purchase was 10.4%. The holding were 85,000 shares as of .

Copernicus Capital Management, LLC initiated holding in UnitedHealth Group Inc. The purchase prices were between $236.02 and $271.13, with an estimated average price of $255.35. The stock is now traded at around $236.08. The impact to a portfolio due to this purchase was 7.61%. The holding were 12,000 shares as of .

Copernicus Capital Management, LLC initiated holding in IQVIA Holdings Inc. The purchase prices were between $109.96 and $144.45, with an estimated average price of $133.07. The stock is now traded at around $135.27. The impact to a portfolio due to this purchase was 7.38%. The holding were 20,000 shares as of .

Copernicus Capital Management, LLC initiated holding in Horizon Therapeutics PLC. The purchase prices were between $16.5 and $25.2, with an estimated average price of $20.53. The stock is now traded at around $23.60. The impact to a portfolio due to this purchase was 4.47%. The holding were 66,000 shares as of .

Copernicus Capital Management, LLC initiated holding in Nevro Corp. The purchase prices were between $35.52 and $62.62, with an estimated average price of $46.85. The stock is now traded at around $62.26. The impact to a portfolio due to this purchase was 0.8%. The holding were 5,000 shares as of .

Copernicus Capital Management, LLC added to a holding in Heron Therapeutics Inc by 46.18%. The purchase prices were between $23.15 and $28.34, with an estimated average price of $26.21. The stock is now traded at around $18.13. The impact to a portfolio due to this purchase was 2.69%. The holding were 135,946 shares as of .

Copernicus Capital Management, LLC sold out a holding in Merck & Co Inc. The sale prices were between $72.92 and $83.17, with an estimated average price of $78.33.

Copernicus Capital Management, LLC sold out a holding in CVS Health Corp. The sale prices were between $52.36 and $69.88, with an estimated average price of $61.96.

Copernicus Capital Management, LLC sold out a holding in WellCare Health Plans Inc. The sale prices were between $230.61 and $282.5, with an estimated average price of $258.4.

Copernicus Capital Management, LLC sold out a holding in Allergan PLC. The sale prices were between $132.09 and $160.79, with an estimated average price of $144.95.